{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:53:23Z","timestamp":1781643203573,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bradykinin-mediated hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is often hard to differentiate from mast cell (MC) mediated diseases. MCs can be activated by numerous stimuli, leading to the release of various mediators. Recently, crosstalk between MCs and the complement system has been reported. Clinical observations report a higher prevalence of MC-mediated diseases in the HAE-C1INH population than in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate MC activation in HAE-C1INH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples from patients during angioedema attack (HAE-A) and during symptom-free period (HAE-SF), as well as from non-angioedema control subjects were examined. Patients and control subjects had no history of allergic disease and normal levels of both nutritional and inhalant specific IgE. Tryptase, chymase, platelet-activating factor (PAF), leukotriene B4 (LTB4), diamine oxidase (DAO), and eosinophil cationic protein (ECP) were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum level of chymase was higher in both HAE-C1INH groups than in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020 in both comparisons), while no difference was found between the HAE-A and HAE-SF groups. DAO and ECP did not differ from the control group, but their levels increased during angioedema attack compared to the asymptomatic state (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018 and 0.004, respectively). No difference was found in the levels of the other mediators in any comparison. Chymase levels during the symptom-free period were significantly lower in those patients who had more than 3 HAE attack in the three months following sampling than in those who had less than that (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). No other mediators showed a difference between these two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significantly higher chymase levels in HAE-C1INH patients raise the possibility of the activation of a specific subset of MCs in HAE-C1INH patients. Elevation of DAO and ECP levels during HAE attacks indicates the involvement of bradykinin-independent pathways in edema formation during HAE attacks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04294-6","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:26:57Z","timestamp":1773462417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mast cell mediators in hereditary angioedema"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3055-420X","authenticated-orcid":false,"given":"Hanga R\u00e9ka","family":"Horv\u00e1th","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6104-5446","authenticated-orcid":false,"given":"No\u00e9mi","family":"Andr\u00e1si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5698-5633","authenticated-orcid":false,"given":"Eszter","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-9517","authenticated-orcid":false,"given":"\u00c9va","family":"Imreh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-1721","authenticated-orcid":false,"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"4294_CR1","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022."},{"key":"4294_CR2","doi-asserted-by":"crossref","unstructured":"Patel G, Pongracic JA. Hereditary and acquired angioedema. Allergy Asthma Proc. 2019;40(6):441-5.","DOI":"10.2500\/aap.2019.40.4267"},{"issue":"2","key":"4294_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12016-016-8561-8","volume":"51","author":"BL Zuraw","year":"2016","unstructured":"Zuraw BL, Christiansen SC. HAE Pathophysiology and Underlying Mechanisms. Clin Rev Allergy Immunol. 2016;51(2):216\u201329.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4294_CR4","unstructured":"Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS, et al. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J Allergy Clin Immunol. 2024."},{"issue":"1","key":"4294_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/all.14881","volume":"77","author":"JS Dahlin","year":"2022","unstructured":"Dahlin JS, Maurer M, Metcalfe DD, Pejler G, Sagi-Eisenberg R, Nilsson G. The ingenious mast cell: Contemporary insights into mast cell behavior and function. Allergy. 2022;77(1):83\u201399.","journal-title":"Allergy"},{"issue":"3","key":"4294_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12016-019-08769-2","volume":"58","author":"D Elieh Ali Komi","year":"2020","unstructured":"Elieh Ali Komi D, W\u00f6hrl S, Bielory L. Mast Cell Biology at Molecular Level: a Comprehensive Review. Clin Rev Allergy Immunol. 2020;58(3):342\u201365.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"4294_CR7","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1111\/all.14413","volume":"75","author":"D Elieh Ali Komi","year":"2020","unstructured":"Elieh Ali Komi D, Shafaghat F, Kovanen PT, Meri S. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy. 2020;75(11):2818\u201328.","journal-title":"Allergy"},{"issue":"2","key":"4294_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cei.12952","volume":"188","author":"R Lubbers","year":"2017","unstructured":"Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017;188(2):183\u201394.","journal-title":"Clin Exp Immunol"},{"key":"4294_CR9","doi-asserted-by":"publisher","first-page":"615236","DOI":"10.3389\/fimmu.2020.615236","volume":"11","author":"PW West","year":"2020","unstructured":"West PW, Bahri R, Garcia-Rodriguez KM, Sweetland G, Wileman G, Shah R, et al. Interleukin-33 Amplifies Human Mast Cell Activities Induced by Complement Anaphylatoxins. Front Immunol. 2020;11:615236.","journal-title":"Front Immunol"},{"issue":"6","key":"4294_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2222.1997.tb01193.x","volume":"27","author":"T Brunn\u00e9e","year":"1997","unstructured":"Brunn\u00e9e T, Reddigari SR, Shibayama Y, Kaplan AP, Silverberg M. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy. 1997;27(6):653\u201363.","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"4294_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000024284","volume":"120","author":"O Noga","year":"1999","unstructured":"Noga O, Brunn\u00e9e T, Sch\u00e4per C, Kunkel G. Heparin, derived from the mast cells of human lungs is responsible for the generation of kinins in allergic reactions due to the activation of the contact system. Int Arch Allergy Immunol. 1999;120(4):310\u20136.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"4294_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.immuni.2011.02.008","volume":"34","author":"C Oschatz","year":"2011","unstructured":"Oschatz C, Maas C, Lecher B, Jansen T, Bj\u00f6rkqvist J, Tradler T, et al. Mast Cells Increase Vascular Permeability by Heparin-Initiated Bradykinin Formation In Vivo. Immunity. 2011;34(2):258\u201368.","journal-title":"Immunity"},{"issue":"4","key":"4294_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s40521-015-0067-8","volume":"2","author":"A Sala-Cunill","year":"2015","unstructured":"Sala-Cunill A, Guilarte M. The Role of Mast Cells Mediators in Angioedema Without Wheals. Curr Treat Options Allergy. 2015;2(4):294\u2013306.","journal-title":"Curr Treat Options Allergy"},{"key":"4294_CR14","doi-asserted-by":"publisher","first-page":"1399459","DOI":"10.3389\/fimmu.2024.1399459","volume":"15","author":"G Porebski","year":"2024","unstructured":"Porebski G, Dziadowiec A, Rybka H, Kitel R, Kwitniewski M. Mast cell degranulation and bradykinin-induced angioedema - searching for the missing link. Front Immunol. 2024;15:1399459.","journal-title":"Front Immunol"},{"issue":"3","key":"4294_CR15","doi-asserted-by":"publisher","first-page":"e12135","DOI":"10.1002\/clt2.12135","volume":"12","author":"L Sundler Bj\u00f6rkman","year":"2022","unstructured":"Sundler Bj\u00f6rkman L, Persson B, Aronsson D, Skattum L, Nordenfelt P, Egesten A. Comorbidities in hereditary angioedema-A population-based cohort study. Clin Transl Allergy. 2022;12(3):e12135.","journal-title":"Clin Transl Allergy"},{"issue":"11","key":"4294_CR16","doi-asserted-by":"publisher","first-page":"100833","DOI":"10.1016\/j.waojou.2023.100833","volume":"16","author":"HR Horv\u00e1th","year":"2023","unstructured":"Horv\u00e1th HR, Szil\u00e1gyi D, Andr\u00e1si N, Balla Z, Visy B, Farkas H. Hypersensitivity reactions amongst Hungarian Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency. World Allergy Organ J. 2023;16(11):100833.","journal-title":"World Allergy Organ J"},{"issue":"6","key":"4294_CR17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.anai.2023.08.012","volume":"131","author":"SC Christiansen","year":"2023","unstructured":"Christiansen SC, Wilmot J, Castaldo AJ, Zuraw BL. The US Hereditary Angioedema Association Scientific Registry: hereditary angioedema demographics, disease severity, and comorbidities. Ann Allergy Asthma Immunol. 2023;131(6):766\u2013e748.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"4294_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/all.12330","volume":"69","author":"S Smolinska","year":"2014","unstructured":"Smolinska S, Jutel M, Crameri R, O\u2019Mahony L. Histamine and gut mucosal immune regulation. Allergy. 2014;69(3):273\u201381.","journal-title":"Allergy"},{"issue":"2","key":"4294_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.11613\/BM.2011.019","volume":"21","author":"RZ Topic","year":"2011","unstructured":"Topic RZ, Dodig S. Eosinophil cationic protein\u2013current concepts and controversies. Biochem Med (Zagreb). 2011;21(2):111\u201321.","journal-title":"Biochem Med (Zagreb)"},{"issue":"3","key":"4294_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10238-018-0499-0","volume":"18","author":"F Arcoleo","year":"2018","unstructured":"Arcoleo F, Lo Pizzo M, Misiano G, Milano S, Romano GC, Muggeo V, et al. The complex alteration in the network of IL-17-type cytokines in patients with hereditary angioedema. Clin Exp Med. 2018;18(3):355\u201361.","journal-title":"Clin Exp Med"},{"issue":"3 Pt 1","key":"4294_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0091-6749(88)90012-7","volume":"82","author":"CM Brickman","year":"1988","unstructured":"Brickman CM, Frank MM, Kaliner M. Urine-histamine levels in patients with hereditary angioedema (HAE). J Allergy Clin Immunol. 1988;82(3 Pt 1):403\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4294_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.intimp.2014.03.007","volume":"20","author":"M Demirt\u00fcrk","year":"2014","unstructured":"Demirt\u00fcrk M, Gelincik A, C\u0131nar S, Kilercik M, Onay-Ucar E, \u00c7olako\u011flu B, et al. Increased eNOS levels in hereditary angioedema. Int Immunopharmacol. 2014;20(1):264\u20138.","journal-title":"Int Immunopharmacol"},{"key":"4294_CR23","doi-asserted-by":"crossref","unstructured":"Dyga W, Obtulowicz A, Mikolajczyk T, Bogdali A, Dubiela P, Obtulowicz K. The role of bradykinin receptors in hereditary angioedema due to C1-inhibitor deficiency. Int J Mol Sci. 2022;23(18).","DOI":"10.3390\/ijms231810332"},{"key":"4294_CR24","doi-asserted-by":"publisher","first-page":"106079","DOI":"10.1016\/j.intimp.2019.106079","volume":"78","author":"AL Ferrara","year":"2020","unstructured":"Ferrara AL, Bova M, Petraroli A, Veszeli N, Galdiero MR, Braile M, et al. Hereditary angioedema attack: what happens to vasoactive mediators? Int Immunopharmacol. 2020;78:106079.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4294_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12016-021-08842-9","volume":"60","author":"AL Ferrara","year":"2021","unstructured":"Ferrara AL, Cristinziano L, Petraroli A, Bova M, Gigliotti MC, Marcella S, et al. Roles of Immune Cells in Hereditary Angioedema. Clin Rev Allergy Immunol. 2021;60(3):369\u201382.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"4294_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12016-021-08847-4","volume":"60","author":"E Kajd\u00e1csi","year":"2021","unstructured":"Kajd\u00e1csi E, Veszeli N, Mez\u0151 B, Jandrasics Z, K\u0151halmi KV, Ferrara AL, et al. Pathways of Neutrophil Granulocyte Activation in Hereditary Angioedema with C1 Inhibitor Deficiency. Clin Rev Allergy Immunol. 2021;60(3):383\u201395.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"4294_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/all.12862","volume":"71","author":"S Loffredo","year":"2016","unstructured":"Loffredo S, Bova M, Suffritti C, Borriello F, Zanichelli A, Petraroli A, et al. Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema. Allergy. 2016;71(7):989\u201396.","journal-title":"Allergy"},{"issue":"1","key":"4294_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13023-019-0995-7","volume":"14","author":"B M\u00e1rkus","year":"2019","unstructured":"M\u00e1rkus B, Veszeli N, Temesszentandr\u00e1si G, Farkas H, Kalabay L. Serum fetuin-A, tumor necrosis factor alpha and C-reactive protein concentrations in patients with hereditary angioedema with C1-inhibitor deficiency. Orphanet J Rare Dis. 2019;14(1):67.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4294_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10238-015-0340-y","volume":"16","author":"M Salemi","year":"2016","unstructured":"Salemi M, Mandal\u00e0 V, Muggeo V, Misiano G, Milano S, Colonna-Romano G, et al. Growth factors and IL-17 in hereditary angioedema. Clin Exp Med. 2016;16(2):213\u20138.","journal-title":"Clin Exp Med"},{"key":"4294_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13023-015-0374-y","volume":"10","author":"N Veszeli","year":"2015","unstructured":"Veszeli N, Csuka D, Zotter Z, Imreh \u00c9, J\u00f3zsi M, Benedek S, et al. Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2015;10:156.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4294_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1161\/CIRCRESAHA.117.310978","volume":"122","author":"LJ Dell\u2019Italia","year":"2018","unstructured":"Dell\u2019Italia LJ, Collawn JF, Ferrario CM. Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling. Circ Res. 2018;122(2):319\u201336.","journal-title":"Circ Res"},{"issue":"4","key":"4294_CR32","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1172\/JCI116325","volume":"91","author":"H Urata","year":"1993","unstructured":"Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91(4):1269\u201381.","journal-title":"J Clin Invest"},{"key":"4294_CR33","doi-asserted-by":"publisher","first-page":"918305","DOI":"10.3389\/fimmu.2022.918305","volume":"13","author":"L Hellman","year":"2022","unstructured":"Hellman L, Akula S, Fu Z, Wernersson S. Mast Cell and Basophil Granule Proteases - In Vivo Targets and Function. Front Immunol. 2022;13:918305.","journal-title":"Front Immunol"},{"issue":"5","key":"4294_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000506985","volume":"12","author":"G Pejler","year":"2020","unstructured":"Pejler G. Novel Insight into the in vivo Function of Mast Cell Chymase: Lessons from Knockouts and Inhibitors. J Innate Immun. 2020;12(5):357\u201372.","journal-title":"J Innate Immun"},{"issue":"3","key":"4294_CR35","doi-asserted-by":"publisher","first-page":"L422","DOI":"10.1152\/ajplung.00548.2020","volume":"320","author":"Z Abassi","year":"2021","unstructured":"Abassi Z, Skorecki K, Hamo-Giladi DB, Kruzel-Davila E, Heyman SN. Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease. Am J Physiol Lung Cell Mol Physiol. 2021;320(3):L422\u20139.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"Pt A","key":"4294_CR36","doi-asserted-by":"publisher","first-page":"108269","DOI":"10.1016\/j.intimp.2021.108269","volume":"101","author":"X Lu","year":"2021","unstructured":"Lu X, Liu J, Wei T, Zhou X. Elevated salivary activity of mast cell chymase of periodontitis patients, and a new bradykinin generation cascade, mediating the cross-talks between mast cell and gingival fibroblast. Int Immunopharmacol. 2021;101(Pt A):108269.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"4294_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00418-019-01803-6","volume":"152","author":"D Atiakshin","year":"2019","unstructured":"Atiakshin D, Buchwalow I, Tiemann M. Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol. 2019;152(4):253\u201369.","journal-title":"Histochem Cell Biol"},{"issue":"12","key":"4294_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11274-022-03421-2","volume":"38","author":"L Kettner","year":"2022","unstructured":"Kettner L, Seitl I, Fischer L. Recent advances in the application of microbial diamine oxidases and other histamine-oxidizing enzymes. World J Microbiol Biotechnol. 2022;38(12):232.","journal-title":"World J Microbiol Biotechnol"},{"key":"4294_CR39","doi-asserted-by":"crossref","unstructured":"Jochum C. Histamine intolerance: symptoms, diagnosis, and beyond. Nutrients. 2024;16(8).","DOI":"10.3390\/nu16081219"},{"issue":"3","key":"4294_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/all.13663","volume":"74","author":"T Boehm","year":"2019","unstructured":"Boehm T, Reiter B, Ristl R, Petroczi K, Sperr W, Stimpfl T, et al. Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy. 2019;74(3):583\u201393.","journal-title":"Allergy"},{"issue":"9","key":"4294_CR41","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1046\/j.1365-2222.1999.00542.x","volume":"29","author":"P Venge","year":"1999","unstructured":"Venge P, Bystr\u00f6m J, Carlson M, H\u00e2kansson L, Karawacjzyk M, Peterson C, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999;29(9):1172\u201386.","journal-title":"Clin Exp Allergy"},{"issue":"6070","key":"4294_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/321613a0","volume":"321","author":"JD Young","year":"1986","unstructured":"Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986;321(6070):613\u20136.","journal-title":"Nature"},{"issue":"1","key":"4294_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/ACI.0000000000000602","volume":"20","author":"J Ho","year":"2020","unstructured":"Ho J, Earls P, Harvey RJ. Systemic biomarkers of eosinophilic chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2020;20(1):23\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"4294_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.15586\/aei.v49i2.50","volume":"49","author":"P Pritam","year":"2021","unstructured":"Pritam P, Manna S, Sahu A, Swain SS, Ramchandani S, Bissoyi S, et al. Eosinophil: a central player in modulating pathological complexity in asthma. Allergol Immunopathol (Madr). 2021;49(2):191\u2013207.","journal-title":"Allergol Immunopathol (Madr)"},{"key":"4294_CR45","doi-asserted-by":"crossref","unstructured":"Wada A, Sawada Y, Sugino H, Nakamura M. Angioedema and fatty acids. Int J Mol Sci. 2021;22(16).","DOI":"10.3390\/ijms22169000"},{"key":"4294_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40413-016-0094-3","volume":"9","author":"DD Metcalfe","year":"2016","unstructured":"Metcalfe DD, Pawankar R, Ackerman SJ, Akin C, Clayton F, Falcone FH, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J. 2016;9:7.","journal-title":"World Allergy Organ J"},{"key":"4294_CR47","unstructured":"Nussberger J, Cugno M, Fau - Cicardi M, Cicardi M, Fau - Agostoni A, Agostoni A. Local bradykinin generation in hereditary angioedema. (0091\u20136749 (Print))."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04294-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:03:59Z","timestamp":1781640239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04294-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4294"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04294-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Semmelweis University, and informed consent was obtained from the participants in accordance with the Declaration of Helsinki (License number: 1067-5\/2018\/E\u00dcIG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hanga R\u00e9ka Horv\u00e1th received travel grants from Takeda and CSL Behring. Henriette Farkas has received research grants from CSL Behring, Takeda and Pharming and served as an advisor for these companies and Kalvista, Intellia, Ionis, Pharvaris, ONO Pharmaceuticals and Biocryst and has participated in clinical trials\/registries for BioCryst, CSL Behring, Pharming, Kalvista, Pharvaris and Takeda. All other authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}